Panel Discussion on COVID-19: How Has the RNA Industry Adapted to Beat the Pandemic
SMi Reports: The 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics.
London, United Kingdom, November 15, 2020 --(PR.com)-- RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy personalised medicines, and treatment of genetic, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%.
Furthermore, the recent advances of AI technology for RNA drug discovery, as well as new strides in the delivery of messenger RNA transcribed in vitro, have triggered a major expansion of the RNA-therapeutics field.
In recent news Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study*
Their co-chair Heinrich Haas, Vice President Formulation and Drug Delivery, BioNTech RNA Pharmaceuticals will be moderating the panel discussion on:
COVID-19: how has the RNA industry adapted to beat the pandemic
• The global collaboration to facilitate development and evaluation of therapeutics, diagnostics and vaccines against COVID-19
• Current mRNA vaccines in development
• How has industry adapted clinical trials and R&D to allow accelerated development?
• How have approval processes been accelerated and will this affect future approval processes post-pandemic?
Panelists:
Troels Koch, Founder & CEO, Aqiventa
Michael Mulqueen, VP Business Development, eTheRNA immunotherapies
Priya Karmali, VP, Technology Innovation and Development, Arcturus Therapeutics
Kirsty Wydenbach, Deputy Unit Manager/Senior Medical Assessor, MHRA
View the full agenda and speaker line-up here: www.therapeutics-rna.com/prcom3
Alongside the panel discussion Priya Karmali, VP, Technology Innovation and Development, Arcturus Therapeutics will also be presenting on:
mRNA and developing a COVID-19 vaccine
• An introduction to Arcturus Therapeutics
• mRNA technologies and the therapeutic potential
• An overview of the LUNAR delivery technology
• Case Study: LUNAR-COV1
A conference not to be missed. Register today for only £499. Register online:
www.therapeutics-rna.com/prcom3
Proudly sponsored by: Thermo Fisher Scientific & eTheRNA inmmunotherapies
* https://www.pfizer.com/news
Contact Information:
For media enquiries contact Jinna Sidhu on Tel: +44 (0)20 7827 6088 / Email: hsidhu@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Furthermore, the recent advances of AI technology for RNA drug discovery, as well as new strides in the delivery of messenger RNA transcribed in vitro, have triggered a major expansion of the RNA-therapeutics field.
In recent news Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study*
Their co-chair Heinrich Haas, Vice President Formulation and Drug Delivery, BioNTech RNA Pharmaceuticals will be moderating the panel discussion on:
COVID-19: how has the RNA industry adapted to beat the pandemic
• The global collaboration to facilitate development and evaluation of therapeutics, diagnostics and vaccines against COVID-19
• Current mRNA vaccines in development
• How has industry adapted clinical trials and R&D to allow accelerated development?
• How have approval processes been accelerated and will this affect future approval processes post-pandemic?
Panelists:
Troels Koch, Founder & CEO, Aqiventa
Michael Mulqueen, VP Business Development, eTheRNA immunotherapies
Priya Karmali, VP, Technology Innovation and Development, Arcturus Therapeutics
Kirsty Wydenbach, Deputy Unit Manager/Senior Medical Assessor, MHRA
View the full agenda and speaker line-up here: www.therapeutics-rna.com/prcom3
Alongside the panel discussion Priya Karmali, VP, Technology Innovation and Development, Arcturus Therapeutics will also be presenting on:
mRNA and developing a COVID-19 vaccine
• An introduction to Arcturus Therapeutics
• mRNA technologies and the therapeutic potential
• An overview of the LUNAR delivery technology
• Case Study: LUNAR-COV1
A conference not to be missed. Register today for only £499. Register online:
www.therapeutics-rna.com/prcom3
Proudly sponsored by: Thermo Fisher Scientific & eTheRNA inmmunotherapies
* https://www.pfizer.com/news
Contact Information:
For media enquiries contact Jinna Sidhu on Tel: +44 (0)20 7827 6088 / Email: hsidhu@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Jinna Sidhu
+44 (0) 20 7827 6088
http://www.therapeutics-rna.com/prcom3
Jinna Sidhu
+44 (0) 20 7827 6088
http://www.therapeutics-rna.com/prcom3
Contact
Categories